ADAbigail Dove

Abigail Dove

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abigail Dove has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Healthy Sleep Mitigates the Association Between Cardiometabolic Disease and Poorer Cognitive and Brain Health

    by Yuyang Miao, Livia Fingerson, Elise Walters, Kathryn DaSilva, Mariam Militonyan, Aleksandra Koycheva, Sakura Sakakibara, Charlotte Sørensen, Shireen Sindi, Abigail Dove

    Background: Cardiometabolic diseases (CMDs), including type 2 diabetes, heart disease, and stroke, are important risk factors for dementia. We examined whether healthy sleep can support cognitive and brain health in people with CMDs. Methods: The study included data from 408 977 adults from the UK Biobank. CMDs were defined using medical records, medication use, and medical history. Sleep patterns were defined using a composite score incorporating sleep duration, chronotype, insomnia symptoms, snoring, and daytime sleepiness. A subsample (n=34 913) underwent brain magnetic resonance imaging; volumes of total brain, gray matter, white matter, hippocampus, and white matter hyperintensities were ascertained. Associations of joint CMD (yes/no) and sleep (healthy, intermediate, poor) status with global and domain‐specific cognitive scores and brain magnetic resonance imaging measures were examined using linear regression models. Results: At baseline, 54017 (13.2%) participants had at least one CMD. In joint exposure analysis, performance in global cognition (β=0.02 [95% CI, 0.01–0.05]), verbal/numeric reasoning (β=0.07 [95% CI, 0.01–0.12]), and processing speed (β=0.07 [95% CI, 0.04–0.10]) was significantly higher among individuals with CMDs and a healthy sleep pattern, compared with those with CMDs and a poor sleep pattern. Similarly, in neuroimaging analyses, participants with CMDs and a healthy versus poor sleep pattern showed significantly larger total brain volume (β=0.22 [95% CI, 0.08–0.35]), gray matter volume (β=0.23 [95% CI, 0.09–0.36]), and white matter volume (β=0.19 [95% CI, 0.05–0.33]). Conclusions: Healthy sleep may attenuate the associations of CMDs with poorer cognitive performance and markers of brain atrophy. The findings highlight sleep as a modifiable factor that may support cognitive and brain health in individuals with CMDs.

  • Open Access

    Metabolic syndrome is associated with accelerated brain aging

    by Abigail Dove, Jiao Wang, Rongrong Yang, Sakura Sakakibara, Zoe Arvanitakis, Andrea L. C. Schneider, Rebecca F. Gottesman, Weili Xu

    INTRODUCTION: Metabolic syndrome (MetS) is associated with increased dementia risk, but its relationship with brain aging is unclear. METHODS: The study included 27,375 UK Biobank participants aged 40 to 70 years. MetS was defined as having at least three of five components: central adiposity, hypertension, dyslipidemia, hypertriglyceridemia, and hyperglycemia. Levels of 33 plasma metabolites were measured from baseline blood samples. Brain age was estimated using a machine learning model based on 1079 phenotypes from brain magnetic resonance imaging (MRI) scans and used to calculate brain age gap (BAG, i.e., brain age minus chronological age). RESULTS: Participants with MetS had significantly higher BAG compared to MetS‐free individuals ( β = 1.13; 95% confidence interval [CI]: 0.99 to 1.27). Each individual MetS component was also associated with higher BAG. Eight metabolites significantly mediated the MetS–BAG association (mediation proportion: 2.6% to 16.5%), including apolipoproteins, fatty acids, and inflammatory markers. DISCUSSION: MetS is associated with accelerated brain aging, partly mediated by inflammation and altered lipid metabolism.


  • Open Access

    Association between frailty and major chronic disease-free life expectancy: a large community-based longitudinal study

    by Shuqi Wang, Jiao Wang, Jie Guo, Abigail Dove, Xiuying Qi, Debora Rizzuto, Weili Xu

    We aimed to investigate the extent to which frailty is associated with chronic disease-free life expectancy (LE), focusing on major chronic diseases such as cardiovascular disease [CVD], diabetes, dementia, and cancer, in both males and females. Within the UK Biobank, 392,982 chronic disease-free participants (mean age: 55.8 ± 8.1 years; 55.1% female) were followed for up to 16 years. Frailty at baseline was assessed based on five criteria: self-reported weight loss, exhaustion, low physical activity, slow walking speed, and poor grip strength. All participants were categorized as non-frail (0 criteria), pre-frail (1-2 criteria), and frail (≥3 criteria). CVD, diabetes, dementia, cancer, and death were ascertained through medical records and the death registry. Data were analyzed using parametric proportional hazard regression models with a Gompertz distribution in a multi-state context. At baseline, there were 113,421 (64.3%), 59,553 (33.7%), and 3,516 (2.0%) non-frail, pre-frail, and frail males, respectively, and 125,285 (57.9%), 83,935 (38.8%), and 7,272 (3.3%) corresponding females. At age 50, the estimated chronic disease-free LE (95% confidence interval) for non-frail, pre-frail, and frail males were 20.64 (20.31, 21.01), 18.73 (18.41, 19.13), and 14.75 (14.40, 15.20), with corresponding LE for females of 25.77 (25.34, 26.15), 23.65 (23.22, 24.07), and 19.15 (18.70, 19.67). Respectively, chronic disease-free LE was 5.90 (3.95, 7.84) and 6.62 (4.47, 8.77) years shorter for males and females who were frail compared to non-frail. Frailty is associated with more than 5 years shorter chronic disease-free LE in both males and females.

  • Open Access

    Pain and its association with device-measured activity patterns in older adults: age and sex differences in a population-based cross-sectional study

    by Caroline Lager, Abigail Dove, Debora Rizzuto, Joan Ars, Anne-Marie Boström, Amaia Calderón Larrañaga, Anna-Karin Welmer

    Background: While pain has been widely studied in relation to physical activity (PA), less is known about how habitual patterns of activity relate to pain in older adults. This study examined associations between pain characteristics and activity patterns in older adults, and whether these associations differ by age and sex. Methods: Cross-sectional data from 665 older adults in the Swedish National Study on Aging and Care–Kungsholmen (SNAC-K, 2016–2019) were analysed. PA and sedentary behaviour were measured using the activPAL3™ accelerometer, and pain characteristics were collected via questionnaires. Latent Class Analysis identified three activity classes (named Active- , Balanced and Sedentary Movers ) based on steps/day, sedentary time- and bout duration, light PA, moderate-to-vigorous PA, and number of light-/moderate-to-vigorous PA events. Multinomial logistic regression assessed associations between activity classes and pain, testing modification by age and sex. Results: In the total sample, higher pain intensity was associated with membership in the Sedentary Movers class (RRR: 2.16, 95% CI: 1.06, 4.40, p = 0.034), characterised by low PA and predominant sedentary behaviour, compared with the Active Movers (reference), characterised by high activity levels with substantial light- and moderate-to-vigorous PA. The interaction analysis displayed that associations were concentrated in women and the oldest-old (≥ 80 years). No significant associations were observed for pain and the Balanced Movers vs. Active Movers classes. Conclusion: Activity patterns characterised by high sedentary behaviour were associated with specific pain characteristics in older adults, particularly among women and the oldest-old. Longitudinal studies are needed to clarify the direction of these associations.


  • Open Access

    Trajectory of depression occurrence before, during, and after dementia diagnosis: A population-based study

    by Wenzhe Yang, Weiwei Li, Sakura Sakakibara, Jiao Wang, Marc Guitart-Masip, Xiuying Qi, Abigail Dove, Weili Xu

    Depression and dementia commonly co-occur, yet little is known about depression trajectories across dementia stages. We aimed to map depression occurrence before, during, and after dementia diagnosis, and to identify factors associated with depression among individuals with dementia. This study included 10,051 participants from the Swedish Twin Registry. Participants with incident dementia (n = 2677) were matched with up to 3 controls (n = 7374) by birth year and sex. Depression and dementia diagnoses and their dates were ascertained based on medical records from the National Patient Registry. Conditional Poisson regression estimated incidence rate ratios for depression, while generalized estimating equations examined odds ratios for factors associated with depression. Compared with controls, depression risk among participants with dementia began to increase 6 years pre-diagnosis (incidence rate ratio [95% confidence interval] 2.32 [1.24–4.35]) and peaked during the year of dementia diagnosis (10.38 [7.33–14.69]). Depression risk remained elevated but gradually declined over the following 4 years (3.10 [1.67–5.77]). Female sex (odds ratio 2.21 [1.63–2.99]), smoking (1.58 [1.20–2.08]), heavy drinking (1.88 [1.10–3.21]), and stroke (1.94 [1.31–2.88]) were associated with higher odds of depression before dementia diagnosis, whereas being single (1.71 [1.10–2.37]) and having a history of cancer (1.35 [1.05–1.79]) were associated with post-diagnosis depression. Overall, these findings indicate that depression risk rises before, peaks at, and remains elevated after dementia diagnosis, with specific demographic (sex, marital status) and health-related factors (smoking, alcohol use, stroke, cancer) contributing to its occurrence among individuals with dementia.

  • Open Access

    Estimated glucose disposal rate is associated with brain aging and dementia among diabetes-free older adults

    by Jiao Wang, Shuqi Wang, Abigail Dove, Sakura Sakakibara, Stéphanie Paillard-Borg, Marc Guitart-Masip, Jirong Yue, Weili Xu

    Background: To investigate the association of estimated glucose disposal rate (eGDR), a validated measure of insulin resistance (IR), with brain aging and dementia among diabetes-free people. Methods: This study included 258 732 diabetes- and dementia-free adults aged ≥55 from UK Biobank, including 15 389 participants who underwent brain MRI scans. eGDR was assessed by a well-established formula. Brain age gap (BAG) was calculated as difference between machine learning-predicted brain age and chronological age. Dementia was ascertained based on medical records. Data were analyzed using Cox, Laplace, and linear regression. Results: Over the follow-up, 7063 participants developed dementia. The hazard ratios of dementia for eGDR quartiles 2-4 compared to eGDR quartile 1 were 0.88 (0.81, 0.96), 0.83 (0.76, 0.92), and 0.73 (0.66, 0.82), respectively. High eGDR was further associated with 1.31 (0.81, 1.80) years later onset of dementia. Those with high eGDR had 2.09 (1.74, 2.45) years younger brain age than chronological age. Among APOE ɛ4 carriers, those with high eGDR had 14% lower incidence of dementia and a 1.77-year gap between brain age and chronological age (p-for-interaction < .001). Conclusion: Higher eGDR is associated with prolonged onset of dementia and delayed brain aging among diabetes-free individuals, and could buffer genetic risk of APOE ɛ4.


  • Open Access

    Plant-Based Diet Quality, Healthy Lifestyle, and Dementia Risk in Older Adults With Cardiometabolic Diseases

    by Michelle M. Dunk, Abigail Dove, Jiao Wang, Sakura Sakakibara, Adrián Carballo-Casla, Weili Xu


  • Open Access

    Cardiorespiratory Fitness, Multimorbidity Risk, and 15-Year Trajectories in Chronic Disease Accumulation

    by Liyao Xu, Shuqi Wang, Maiwulamujiang Maimaitiyiming, Wenzhe Yang, Sakura Sakakibara, Xiuying Qi, Yaogang Wang, Abigail Dove


  • Open Access

    Poor sleep health is associated with older brain age: the role of systemic inflammation

    by Yuyang Miao, Jiao Wang, Xuerui Li, Jie Guo, Maria M. Ekblom, Shireen Sindi, Qiang Zhang, Abigail Dove


  • Metabolic Syndrome and Incidence of Parkinson Disease

    by Xinjie Zhang, Jiao Wang, Abigail Dove, Ting Yu, Qiang Li, Rebecca F. Gottesman, Weili Xu

    The association between metabolic syndrome (MetS) and incident Parkinson disease (PD) remains equivocal. We aimed to investigate the association of MetS and its components with the risk of PD and to explore the role of genetic background in the MetS-PD association. This prospective cohort study included PD-free adults aged 37-73 years from the UK Biobank. MetS was defined as presence of 3 or more of the following: elevated waist circumference (≥102 cm for men; ≥88 cm for women), hypertension (systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or use of antihypertensive medication), dyslipidemia (high-density lipoprotein cholesterol PD) was calculated based on the presence of 26 PD-related alleles and categorized as low, moderate, or high. Data were analyzed using Cox regression. In addition, a meta-analysis was conducted by integrating the present UK Biobank data with findings from 8 other observational studies. The study included 467,200 participants (mean age 56.53 ± 8.09 years; 54.26% female), 177,407 (37.97%) of whom had MetS. Over the follow-up (6,605.9 × 1,000 person-years), 3,222 participants developed PD (5.01 [95% CI 4.84-5.18] per 10,000 person-years, age-specified and sex-specified). The hazard ratio of PD was 1.39 (1.11-1.74) for participants with MetS compared with those who were MetS-free. Furthermore, having a higher number of MetS components was dose-dependently associated with higher PD risk (HR: 1.14 [1.05-1.24]; p for trend = 0.001). In addition, PD risk was highest among participants with MetS and high PRSPD (HR: 2.58 [2.12-3.14]; p for interaction = 0.002). In a meta-analysis of 24,789,538 participants with 98,582 incident cases of PD, the pooled relative risk of PD was 1.29 (1.15-1.44) for participants with MetS. Supported by evidence from meta-analysis, MetS was associated with higher risk of incident PD, especially in people with a high genetic predisposition for PD.